0000899243-22-025399.txt : 20220706 0000899243-22-025399.hdr.sgml : 20220706 20220706165410 ACCESSION NUMBER: 0000899243-22-025399 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220705 FILED AS OF DATE: 20220706 DATE AS OF CHANGE: 20220706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peters Richard CENTRAL INDEX KEY: 0001697628 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37695 FILM NUMBER: 221069421 MAIL ADDRESS: STREET 1: MERRIMACK PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQUARE, SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: YUMANITY THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001445283 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 GUEST STREET STREET 2: SUITE 4410 CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-409-5300 MAIL ADDRESS: STREET 1: 40 GUEST STREET STREET 2: SUITE 4410 CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140813 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC DATE OF NAME CHANGE: 20080916 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-05 0 0001445283 YUMANITY THERAPEUTICS, INC. YMTX 0001697628 Peters Richard C/O YUMANITY THERAPEUTICS, INC 40 GUEST STREET, SUITE 4410 BOSTON MA 02135 1 1 0 0 President and CEO Common Stock 2022-07-05 4 S 0 4584 1.8491 D 100918 D Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. /s/ Richard Peters 2022-07-06